Busting the breast cancer with astrazeneca's gefinitib
Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. Epidermal growth factor receptors (EGFRs) and their respective ligands have been blamed for the pathogenesis and resistance to treatment in specific breast cancer cases. With EGFR...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley Open Access
2023
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/106928/1/Busting%20the%20breast%20cancer%20with%20astrazeneca%27s%20gefinitib.pdf http://psasir.upm.edu.my/id/eprint/106928/ https://www.hindawi.com/journals/aps/2023/8127695/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
my.upm.eprints.106928 |
|---|---|
| record_format |
eprints |
| spelling |
my.upm.eprints.1069282024-10-17T06:57:40Z http://psasir.upm.edu.my/id/eprint/106928/ Busting the breast cancer with astrazeneca's gefinitib Chemmalar, S. Intan Shameha, A. R. Che Abdullah, Che Azurahanim Ab Razak, Nor Asma Mohamad Yusof, Loqman Ajat, Mokrish Chan, Kim Wei Abu Bakar Zakaria, Md Zuki Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. Epidermal growth factor receptors (EGFRs) and their respective ligands have been blamed for the pathogenesis and resistance to treatment in specific breast cancer cases. With EGFR having four homologues: EGFR1, EGFR2, EGFR3, and EGFR4, in-depth understanding of EGFR biology led to the discovery of small-molecule inhibitors and antibodies against this receptor. Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast cancer and is supported by a multiplicity of experiments. Unfortunately, in clinical trials, GEF did not show the outcomes expected with complete response and disease progress. This is due to incomplete understanding of the molecular mechanisms involved in EGFR signaling and endocrine sensitivity. Hence, additional in-depth experiments are needed regarding various molecular pathways and crosstalk pathways to comprehend GEF’s action mechanism thoroughly in breast cancer patients. In this review, the role of EGFR in the development and pathogenesis of breast cancer and the pharmacokinetics and pharmacotherapy of GEF for the treatment of breast cancer have been elaborated. Nanomedicines synthesized with GEF have shown positive experimental response, paving a promising path for GEF against breast cancer. Wiley Open Access 2023-12-04 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/106928/1/Busting%20the%20breast%20cancer%20with%20astrazeneca%27s%20gefinitib.pdf Chemmalar, S. and Intan Shameha, A. R. and Che Abdullah, Che Azurahanim and Ab Razak, Nor Asma and Mohamad Yusof, Loqman and Ajat, Mokrish and Chan, Kim Wei and Abu Bakar Zakaria, Md Zuki (2023) Busting the breast cancer with astrazeneca's gefinitib. Advances in Pharmacological and Pharmaceutical Sciences, 2023. art. no. 8127695. pp. 1-26. ISSN 2633-4682; ESSN: 2633-4690 https://www.hindawi.com/journals/aps/2023/8127695/ 10.1155/2023/8127695 |
| institution |
Universiti Putra Malaysia |
| building |
UPM Library |
| collection |
Institutional Repository |
| continent |
Asia |
| country |
Malaysia |
| content_provider |
Universiti Putra Malaysia |
| content_source |
UPM Institutional Repository |
| url_provider |
http://psasir.upm.edu.my/ |
| language |
English |
| description |
Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. Epidermal growth factor receptors (EGFRs) and their respective ligands have been blamed for the pathogenesis and resistance to treatment in specific breast cancer cases. With EGFR having four homologues: EGFR1, EGFR2, EGFR3, and EGFR4, in-depth understanding of EGFR biology led to the discovery of small-molecule inhibitors and antibodies against this receptor. Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast cancer and is supported by a multiplicity of experiments. Unfortunately, in clinical trials, GEF did not show the outcomes expected with complete response and disease progress. This is due to incomplete understanding of the molecular mechanisms involved in EGFR signaling and endocrine sensitivity. Hence, additional in-depth experiments are needed regarding various molecular pathways and crosstalk pathways to comprehend GEF’s action mechanism thoroughly in breast cancer patients. In this review, the role of EGFR in the development and pathogenesis of breast cancer and the pharmacokinetics and pharmacotherapy of GEF for the treatment of breast cancer have been elaborated. Nanomedicines synthesized with GEF have shown positive experimental response, paving a promising path for GEF against breast cancer. |
| format |
Article |
| author |
Chemmalar, S. Intan Shameha, A. R. Che Abdullah, Che Azurahanim Ab Razak, Nor Asma Mohamad Yusof, Loqman Ajat, Mokrish Chan, Kim Wei Abu Bakar Zakaria, Md Zuki |
| spellingShingle |
Chemmalar, S. Intan Shameha, A. R. Che Abdullah, Che Azurahanim Ab Razak, Nor Asma Mohamad Yusof, Loqman Ajat, Mokrish Chan, Kim Wei Abu Bakar Zakaria, Md Zuki Busting the breast cancer with astrazeneca's gefinitib |
| author_facet |
Chemmalar, S. Intan Shameha, A. R. Che Abdullah, Che Azurahanim Ab Razak, Nor Asma Mohamad Yusof, Loqman Ajat, Mokrish Chan, Kim Wei Abu Bakar Zakaria, Md Zuki |
| author_sort |
Chemmalar, S. |
| title |
Busting the breast cancer with astrazeneca's gefinitib |
| title_short |
Busting the breast cancer with astrazeneca's gefinitib |
| title_full |
Busting the breast cancer with astrazeneca's gefinitib |
| title_fullStr |
Busting the breast cancer with astrazeneca's gefinitib |
| title_full_unstemmed |
Busting the breast cancer with astrazeneca's gefinitib |
| title_sort |
busting the breast cancer with astrazeneca's gefinitib |
| publisher |
Wiley Open Access |
| publishDate |
2023 |
| url |
http://psasir.upm.edu.my/id/eprint/106928/1/Busting%20the%20breast%20cancer%20with%20astrazeneca%27s%20gefinitib.pdf http://psasir.upm.edu.my/id/eprint/106928/ https://www.hindawi.com/journals/aps/2023/8127695/ |
| _version_ |
1814054616788107264 |
| score |
13.211869 |